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plan database taking any of 5 long-acting ADHD medications to determine daily 
average consumption (DACON; pills per day) and ADHD pharmacy costs for LDX
compared with other therapies. METHODS: ADHD subjects aged 18–55 years with
at least one prescription for atomoxetine (n  513), methylphenidate (n  546), dex-
methylphenidate (n  124), mixed amphetamine salts (n  1,514), or LDX (n  246)
from July 1, 2007 through October 31, 2007 were studied retrospectively. Subjects
were continuously enrolled for 6 months before (baseline) and 6 months after (follow-
up) their ﬁ rst qualifying prescription. Subjects with an ICD-9 code for ADHD, but
with no ADHD prescriptions at baseline, were retained. Means were compared using
student’s t-test, proportions using chi-square, and ADHD medication costs in the 
follow-up period using Wilcoxon Mann Whitney test. RESULTS: The median number 
of LDX prescriptions (4) and days supplied (113) were highest (p  0.0001) compared
with all other medications in the follow-up period. Mean DACON was lowest for 
LDX (1.06; p  0.0001) and LDX had the highest proportion of patients (87.4%) 
with a DACON a 1. Higher DACON was associated with higher median cost for all
drugs (p  0.0001 for each), but incremental costs were lowest for LDX. CONCLU-
SIONS: Compared with four other drugs, LDX users had the lowest DACON, the 
highest proportion of patients with a DACON a 1, and longest therapy use in the
follow-up period, suggesting both real-world effectiveness and the possibility of better
patient compliance with LDX. Supported by funding from Shire Pharmaceutical 
Development Inc.
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DEPRESSION IN 2004–5
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
University of Nebraska Medical Center, Omaha, NE, USA
OBJECTIVES: To inform providers and payers on the impact of depression in chronic 
medical disorders (CMD) in the United States (US), we studied national estimates of 
health service use and related costs in CMD patients with and without depression.
METHODS: For the retrospective analysis, we extracted data on /18 year-
old employed adults from the pooled 2004–5 Medical Expenditure Panel Survey. 
Data included ICD-9-CM-coded CMD (hyperlipidemia, heart disease, arthritis/other
joint-disorders, chronic obstructive pulmonary disease, hypertension, or diabetes),
depression, health service use (ambulatory, in-patient, and emergency department
visits and prescription medications) and related costs adjusted to 2005 US dollars. We
weighted sample estimates and 95% conﬁ dence limits (CL) using the Taylor expansion 
method. For CMD patients with and without depression, in univariate analyses using 
t-tests, we compared the mean number of ambulatory, in-patient, and emergency
department visits and prescription medications and related costs. RESULTS: On an 
average, CMD patients with depression (n  999) did signiﬁ cantly differ from those 
without depression (n  8739) by number of ambulatory visits (7.5, 95% CL: 6.9–8.1
vs. 4.6, 95% CL: 4.4–4.8, p  0.001) and related costs ($973, 95% CL: 867–1,094
vs. $567, 95% CL: 534–601 p  0.001) and by number of prescription drugs used 
(16.8, 95% CL:15.2–18.5 vs. 9.2, 95% CL:8.9–9.6, p  0.001) and related costs 
($1,012, 95% CL:918–1117 vs. $469, 95% CL: 442–497, p  0.001). However, CMD 
patients with depression did not signiﬁ cantly differ from those without depression for 
average number of inpatient hospital days or emergency department visits (p  0.05). 
CONCLUSIONS: Compared with CMD patients without depression, those with 
depression report 1.6- and 1.7-times higher ambulatory visits and related costs, and 
1.8- and 2.2-times higher mean number of prescription medications and related costs.
Factors associated with signiﬁ cant increases in health service use and related costs in
CMD patients with depression than those without depression need further study.
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OBJECTIVES: To examine hospitalization use and health care costs of elderly MDD
patients treated with escitalopram compared to those treated with either generic SSRIs 
or SNRIs. METHODS: Elderly MDD patients (age 65) initiated on escitalopram, a
generic SSRI, or SNRIs were identiﬁ ed in the Ingenix Impact Database (2003–2007). 
Hospitalization rates, length of stay, and health care costs were examined over the 
6-month period following therapy initiation (analysis period). Logistic and negative 
binomial regressions were used to compare the rate and days of hospitalization,
respectively. Wilcoxon tests were used to compare costs descriptively. General Linear
Model regression was conducted to control for patient characteristics including demo-
graphics, comorbidities, and baseline medical resource use. RESULTS: A total of 1850
elderly patients initiated on escitalopram, 2668 on generic SSRIs, and 1053 on SNRIs.
Escitalopram patients had higher comorbidities, health care utilization, and costs at 
baseline than generic SSRI and SNRI patients. Logistic regression showed that esci-
talopram patients were less likely to be hospitalized in the analysis period than generic 
SSRI (OR  0.81, P  0.0071) or SNRI patients (OR  0.88, P  0.1870). Negative
binomial regression showed that escitalopram patients had fewer hospitalization days
than generic SSRI (IRR  0.79, P  0.0416) and SNRI patients (IRR  0.74, P 
0.0442), which translated into 54.0 and 70.6 more days per 100 patients for the
generic SSRI and SNRI patients over 6 months, respectively. Escitalopram patients had
a $3,758 cost reduction during the analysis period, signiﬁ cantly greater than the cost
reductions for generic SSRI and SNRI patients of $951 and $562, respectively (both 
P  0.0001). GLM regression indicated that the 6-month risk-adjusted total health 
care costs for escitalopram patients were $985 (P  0.0758) and $1,889 (P  0.0080) 
lower than for generic SSRI and SNRI patients, respectively. CONCLUSIONS: Com-
pared to elderly MDD patients initiated on either generic SSRIs or SNRIs, patients
initiated on escitalopram had signiﬁ cantly fewer hospitalization days and lower health 
care costs.
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OBJECTIVES: To determine Quality of Life related to adverse reactions and costs 
using Olanzapine or Quetiapine XR in the treatment of Schizophrenia from an insti-
tutional perspective. METHODS: A Discrete Event model using Arena software was 
designed to calculate costs and Quality of Life (QoL) of Schizophrenia patients. Hos-
pitalization costs and time between relapses were obtained from an observational 
study performed in the Mexican Social Security Institute. This information was used 
to calculate random distributions for the model. Maintenance treatment costs were 
calculated using recommended doses and institutional drugs’ costs. Random distribu-
tions for adverse reactions were obtained from literature. QoL was assessed each year 
and costs were calculated for each patient applying a 3% discount rate. The model 
was run with ﬁ ve hundred patients for each cohort during a six-year period. A single 
variable sensitivity analysis was performed to evaluate the effect on compliance since 
the extended release formulation of Quetiapine is expected to improve compliance. 
Results are presented in US dollars with an exchange rate of 13.5 MXN pesos for 1 
US dollar. RESULTS: Annual average cost of treatment for Olanzapine cohort was 
$4,851 (95% CI, $4,632–$5,085) and for Quetiapine XR cohort $4,533 (95% CI, 
$4,334–$4,750) Average QoL for Olanzapine was 0.840 (95% CI, 0.839–0.842) and
for Quetiapine was 0.859 (95% CI, 0.857–0.861). The sensitivity analysis results 
showed a better QoL at a lesser cost in the worst assessed scenario with 60% compli-
ance in the Quetiapine XR cohort and 80% compliance in the Olanzapine cohort.
CONCLUSIONS: Quetiapine extended release is an atypical antipsychotic with less 
adverse reactions than Olanzapine that results in a better Quality of Life for patients 
with schizophrenia at a lesser cost for the institution.
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OBJECTIVES: To compare economic outcomes of MDD patients who were treated
with a patented SSRI (escitalopram, citalopram, sertraline, or paroxetine controlled-
release) and were switched to a generic SSRI for non-medical reasons vs. those continu-
ing on the patented SSRI. “Therapeutic substitution,” deﬁ ned as change from a 
branded product to a different generic compound in the same class, is a common 
practice encouraged by low co-pay for the generic products. METHODS: Adult MDD 
patients from the Ingenix Impact Database (2003–2007) were considered “switchers” 
if they were treated with a patented SSRI and switched to a generic SSRI. Those who
had an MDD-related urgent care (hospitalization or emergency room) or psychother-
apy visit in the seven days prior to switching were excluded. Patients who remained 
on the patented SSRI (“non-switchers”) were matched 1:1 to switchers. All-cause, 
mental health and MDD-related urgent care costs over six months were compared 
between switchers and non-switchers and regression models controlled for baseline 
differences. A subgroup analysis was conducted for patients treated with escitalopram. 
RESULTS: The study included 4449 matched pairs, 3304 (74%) of whom started on
escitalopram. Compared to non-switchers, switchers had higher risks of all-cause and 
mental health-related urgent care use (OR  1.15 and 1.34, respectively, P  0.01) and 
higher risk-adjusted MDD-related medical costs ($222, P  0.05). In escitalopram 
subgroup analyses, compared to non-switchers, switchers from escitalopram had even 
higher risks of all-cause (OR  1.21) and mental health-related urgent care use (OR 
 1.41, both P  0.01) and higher MDD-related medical costs ($151, P  0.05). 
CONCLUSIONS: Compared to patients who continued on escitalopram or patented
SSRIs, patients who switched to a generic SSRI incurred more urgent care resource
use and higher MDD-related health care costs. The effects of “therapeutic substitu-
tion” should be carefully examined because increasing utilization of drugs with lower 
acquisition costs may not be a cost-saving strategy, when total health care costs are 
considered.
